"Okay time for a bit of weekend speculation shareholders!"
Thanks for that post CPA. It has prompted me to have a bit of a closer look at the MST report.
I do like this concept -
"Our model assumes a deal is achieved upon approval by the FDA to commence first in human TAVR trials of the
DurAVR™ valve in CY21, based on an upfront payment of US$40m, 15% royalty rate on sales of the DurAVR™ valve and
TAVR delivery system as a kit. We use a probability of success of 32%"
I would think that AVR management may have had some input into that assumption and it does mean that the company retains the option to develop further products.
Unless I am not looking in the right place I don't think the cash flow forecast takes into account any funds raised from conversion of options. Just the listed oppies should add approx $19m to the coffers by December 2021 so there should not be a great need to access a lot of further funding from the Mercer deal.
Happy to sit and wait and watch.
- Forums
- ASX - By Stock
- FNN Presentation .. WOW!
"Okay time for a bit of weekend speculation shareholders!"Thanks...
-
- There are more pages in this discussion • 66 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$15.00 |
Change
0.150(1.01%) |
Mkt cap ! $317.0M |
Open | High | Low | Value | Volume |
$15.00 | $15.15 | $14.30 | $210.2K | 14.26K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 500 | $14.60 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.00 | 5153 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 500 | 14.600 |
1 | 60 | 14.350 |
1 | 40 | 14.320 |
1 | 38 | 14.260 |
1 | 200 | 14.200 |
Price($) | Vol. | No. |
---|---|---|
15.000 | 5153 | 3 |
15.150 | 204 | 1 |
15.350 | 2000 | 1 |
15.500 | 44 | 1 |
16.030 | 999 | 1 |
Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |